| 3676- | Ash, | Effect of Withania somnifera (Ashwagandha) root extract on amelioration of oxidative stress and autoantibodies production in collagen-induced arthritic rats |
| - | in-vivo, | Arthritis, | NA |
| 3668- | Ash, | Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver |
| - | NA, | AD, | NA |
| 3669- | Ash, | Withanamides in Withania somnifera fruit protect PC-12 cells from beta-amyloid responsible for Alzheimer's diseas |
| - | in-vitro, | AD, | PC12 |
| 3670- | Ash, | Neurodegenerative diseases and Withania somnifera (L.): An update |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3674- | Ash, | Ashwagandha in brain disorders: A review of recent developments |
| - | Review, | NA, | NA |
| 3685- | Ash, | Withania somnifera as a Potential Anxiolytic and Anti-inflammatory Candidate Against Systemic Lipopolysaccharide-Induced Neuroinflammation |
| - | in-vivo, | NA, | NA |
| 3686- | Ash, | Adaptogenic and Anxiolytic Effects of Ashwagandha Root Extract in Healthy Adults: A Double-blind, Randomized, Placebo-controlled Clinical Study |
| - | Study, | NA, | NA |
| 3687- | Ash, | Role of Withaferin A and Its Derivatives in the Management of Alzheimer’s Disease: Recent Trends and Future Perspectives |
| - | Review, | AD, | NA |
| 3688- | Ash, | Withaferin A Suppresses Beta Amyloid in APP Expressing Cells: Studies for Tat and Cocaine Associated Neurological Dysfunctions |
| - | NA, | AD, | SH-SY5Y |
| 3689- | Ash, | Ashwagandha attenuates TNF-α- and LPS-induced NF-κB activation and CCL2 and CCL5 gene expression in NRK-52E cells |
| - | in-vitro, | NA, | NRK52E |
| 3671- | Ash, | Withania somnifera showed neuroprotective effect and increase longevity in Drosophila Alzheimer’s disease model |
| - | in-vivo, | AD, | NA |
| 3672- | Ash, | Critical review of the Withania somnifera (L.) Dunal: ethnobotany, pharmacological efficacy, and commercialization significance in Africa |
| - | Review, | NA, | NA |
| 3170- | Ash, | Withaferin A protects against hyperuricemia induced kidney injury and its possible mechanisms |
| - | in-vitro, | Nor, | NRK52E | - | in-vivo, | NA, | NA |
| 3169- | Ash, | Withaferin A blocks formation of IFN-γ-induced metastatic cancer stem cells through inhibition of the CXCR4/CXCL12 pathway in the UP-LN1 carcinoma cell model |
| - | in-vitro, | GC, | NA |
| 3179- | Ash, | Withaferin A inhibits JAK/STAT3 signaling and induces apoptosis of human renal carcinoma Caki cells |
| - | in-vitro, | RCC, | Caki-1 |
| 3177- | Ash, | Emerging Role of Hypoxia-Inducible Factors (HIFs) in Modulating Autophagy: Perspectives on Cancer Therapy |
| - | Review, | Var, | NA |
| 3176- | Ash, | Apoptosis is induced in leishmanial cells by a novel protein kinase inhibitor withaferin A and is facilitated by apoptotic topoisomerase I-DNA complex |
| - | in-vitro, | NA, | NA |
| 3175- | Ash, | SFN, | Withaferin A and sulforaphane regulate breast cancer cell cycle progression through epigenetic mechanisms |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 |
| 3174- | Ash, | Withaferin A Acts as a Novel Regulator of Liver X Receptor-α in HCC |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | Hep3B | - | in-vitro, | HCC, | HUH7 |
| 3173- | Ash, | Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma |
| - | in-vitro, | neuroblastoma, | NA |
| 3172- | Ash, | Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | Nor, | HL7702 |
| 3171- | Ash, | Unlocking the epigenetic code: new insights into triple-negative breast cancer |
| - | Review, | BC, | NA |
| 3178- | Ash, | Withaferin A Inhibits Neutrophil Adhesion, Migration, and Respiratory Burst and Promotes Timely Neutrophil Apoptosis |
| - | Review, | Nor, | NA |
| 2388- | Ash, | Withaferin A decreases glycolytic reprogramming in breast cancer |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-453 |
| 3168- | Ash, | Withaferin A targeting both cancer stem cells and metastatic cancer stem cells in the UP-LN1 carcinoma cell model |
| - | in-vitro, | Var, | NA |
| 3154- | Ash, | Pharmacokinetics and bioequivalence of Withania somnifera (Ashwagandha) extracts – A double blind, crossover study in healthy adults |
| 3155- | Ash, | Overview of the anticancer activity of withaferin A, an active constituent of the Indian ginseng Withania somnifera |
| - | Review, | Var, | NA |
| 3156- | Ash, | Withaferin A: From ayurvedic folk medicine to preclinical anti-cancer drug |
| - | Review, | Var, | NA |
| 3157- | Ash, | Withaferin A and Ovarian Cancer Antagonistically Regulate Skeletal Muscle Mass |
| - | in-vivo, | Ovarian, | A2780S |
| 3158- | Ash, | Natural products triptolide, celastrol, and withaferin A inhibit the chaperone activity of peroxiredoxin I |
| - | Study, | NA, | NA |
| 3159- | Ash, | Neuroprotective effects of Withania somnifera in the SH-SY5Y Parkinson cell model |
| - | in-vitro, | Park, | SH-SY5Y |
| 3160- | Ash, | Withaferin A: A Pleiotropic Anticancer Agent from the Indian Medicinal Plant Withania somnifera (L.) Dunal |
| - | Review, | Var, | NA |
| 3161- | Ash, | Withaferin A inhibits ferroptosis and protects against intracerebral hemorrhage |
| - | in-vivo, | Stroke, | NA |
| 3163- | Ash, | Rad, | Withaferin A, a steroidal lactone, selectively protects normal lymphocytes against ionizing radiation induced apoptosis and genotoxicity via activation of ERK/Nrf-2/HO-1 axis |
| 3164- | Ash, | Withaferin A alleviates fulminant hepatitis by targeting macrophage and NLRP3 |
| 3165- | Ash, | Inhibitory effect of withaferin A on Helicobacter pylori‑induced IL‑8 production and NF‑κB activation in gastric epithelial cells |
| - | in-vitro, | Nor, | NA |
| 3166- | Ash, | Exploring the Multifaceted Therapeutic Potential of Withaferin A and Its Derivatives |
| - | Review, | Var, | NA |
| 3167- | Ash, | Withaferin A Inhibits the Proteasome Activity in Mesothelioma In Vitro and In Vivo |
| - | in-vitro, | MM, | H226 |
| 3162- | Ash, | Molecular insights into cancer therapeutic effects of the dietary medicinal phytochemical withaferin A |
| - | Review, | Var, | NA |
| 1142- | Ash, | Ashwagandha-Induced Programmed Cell Death in the Treatment of Breast Cancer |
| - | Review, | BC, | MCF-7 | - | NA, | BC, | MDA-MB-231 | - | NA, | Nor, | HMEC |
| 4303- | Ash, | Ashwagandha (Withania somnifera)—Current Research on the Health-Promoting Activities: A Narrative Review |
| - | Review, | AD, | NA |
| 5169- | Ash, | The Tumor Inhibitor and Antiangiogenic Agent Withaferin A Targets the Intermediate Filament Protein Vimentin |
| - | in-vitro, | BC, | MCF-7 |
| 5170- | Ash, | Withaferin A inhibits NF-kappaB activation by targeting cysteine 179 in IKKβ |
| - | Review, | Var, | NA |
| 5171- | Ash, | The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from "Indian winter cherry" |
| - | vitro+vivo, | Pca, | LNCaP | - | vitro+vivo, | Pca, | PC3 |
| 5172- | Ash, | Withaferin-A suppress AKT induced tumor growth in colorectal cancer cells |
| 5173- | Ash, | 2DG, | Withaferin A inhibits lysosomal activity to block autophagic flux and induces apoptosis via energetic impairment in breast cancer cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | BC, | T47D |
| 5174- | Ash, | Withaferin A is a potent inhibitor of angiogenesis |
| - | in-vitro, | Nor, | HUVECs |
| 5175- | Ash, | Withaferin A Induces Proteasome Inhibition, Endoplasmic Reticulum Stress, the Heat Shock Response and Acquisition of Thermotolerance |
| - | in-vitro, | Cerv, | CCL-102 |
| 4660- | Ash, | Withaferin A Alone and in Combination with Cisplatin Suppresses Growth and Metastasis of Ovarian Cancer by Targeting Putative Cancer Stem Cells |
| - | in-vitro, | Ovarian, | NA |
| 4677- | Ash, | Withaferin A (WFA) inhibits tumor growth and metastasis by targeting ovarian cancer stem cells |
| - | vitro+vivo, | Ovarian, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid